Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17456055 | 0.81 | MCHR1 (0.53) | MCHR1SMN1; SMN2ACHESCN8ASCN1A | |
| SCHEMBL11114435 | 0.81 | SIGMAR1 (0.52) | MCHR1CCR3 | |
| SCHEMBL10371219 | 0.80 | KCNH2 (0.64) | MCHR1SMN1; SMN2OPRK1BCHE | |
| SCHEMBL10368699 | 0.79 | MCHR1 (0.56) | MCHR1SMN1; SMN2OPRK1BCHE | |
| SCHEMBL10608988 | 0.78 | MEN1 (0.59) | MCHR1SMN1; SMN2ACHEBCHE | |
| SCHEMBL17456041 | 0.77 | CYP11B1 (0.53) | MCHR1SMN1; SMN2ACHESCN8ASCN1A | |
| SCHEMBL10608615 | 0.75 | MCHR1 (0.59) | MCHR1SMN1; SMN2ACHESCN8ASCN1A | |
| SCHEMBL10606002 | 0.75 | HRH3 (0.59) | MCHR1SMN1; SMN2ACHEBCHE | |
| Fumaric Acid SCHEMBL10606069 | 0.75 | HRH1 (0.59) | MCHR1SMN1; SMN2BCHE | |
| Maleic Acid SCHEMBL10606063 | 0.75 | HRH1 (0.59) | MCHR1SMN1; SMN2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982666-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-9598398-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| EP-2982666-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-10 | — | — | EP | disclosed |
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | PSEN1, PSEN2, BACE1 | MCHR1 2123/4885SMN1; SMN2 23/4885ACHE 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.